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Abstract
Background:  This work represents an extensive MD simulation / water-dynamics studies on a
series of complexes of inhibitors (leupeptin, E-64, E-64-C, ZPACK) and plant cysteine proteases
(actinidin, caricain, chymopapain, calotropin DI) of papain family to understand the various
interactions, water binding mode, factors influencing it and the structural basis of differential
inhibition.
Results:  The tertiary structure of the enzyme-inhibitor complexes were built by visual interactive
modeling and energy minimization followed by dynamic simulation of 120 ps in water environment.
DASA study with and without the inhibitor revealed the potential subsite residues involved in
inhibition. Though the interaction involving main chain atoms are similar, critical inspection of the
complexes reveal significant differences in the side chain interactions in S2-P2 and S3-P3 pairs due
to sequence differences in the equivalent positions of respective subsites leading to differential
inhibition.
Conclusion:  The key finding of the study is a conserved site of a water molecule near oxyanion
hole of the enzyme active site, which is found in all the modeled complexes and in most crystal
structures of papain family either native or complexed. Conserved water molecules at the ligand
binding sites of these homologous proteins suggest the structural importance of the water, which
changes the conventional definition of chemical geometry of inhibitor binding domain, its shape and
complimentarity. The water mediated recognition of inhibitor to enzyme subsites (Pn...H2O....Sn)
of leupeptin acetyl oxygen to caricain, chymopapain and calotropinDI is an additional information
and offer valuable insight to potent inhibitor design.
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Background
Recently the cysteine proteases of both the plant and an-
imals have received a considerable attention because of
their broad ranges of activities and critical role in the dif-
ferent intracellular / biological / pathological processes
or disorders [1–7]. Uncontrolled proteolysis of certain
proteases e.g. Cathepsins [8,9], Caspases [10,11], Cruza-
in [12,13] causes several pathological disorders. There-
fore the development of potential inhibitors which can
modulate or can moderately control the proteolytic activ-
ity has become a challenge in drug design. For combating
that challenge, some stimulating investigation on the
structural aspects of the complexes on those kind of
cysteine protease with different organic inhibitors or lig-
ands e.g. E-64, E-64-C, leupeptin etc have been done by
x-ray methods, which revealed the 3D-interactional in-
formation about the substrate binding chemistry and the
topological requisite for substrate-mimicking inhibitors.
However, due to the lacking of detail inhibitor binding
information, we are interested to carry out those studies
by MD-simulation methods on plant cysteine protease-
inhibitor complex of papain [14,15] superfamily.
In this regard, beside the common Sn-Pn (n = 1–3) inter-
actional events of the inhibitor with the main chain of the
active site residues in the respective complexes, the role
of the water molecules can not be ignored as they are
sometimes present as conserved at the ligand binding
sites of homologous proteins. These structurally con-
served water molecule can change or influence the shape
and complimentarity of the inhibitor site, thus affect
strategies for therapeutic design. So, in order to get valu-
able insight of the characteristics of the inhibitor, the
modeled inhibitor-enzyme complex structures are ana-
lyzed in detail and compared with the crystallographic
information. The model structures of the enzyme-inhib-
itor complexes are built for the present study using tem-
plate of available x-ray structure of enzyme-inhibitor
complexes from papain family. In each complex struc-
ture, either from a x-ray or model study, it is evident that
binding and catalysis is a two fold mechanism and in
each case the subsite (Sn-Pn) interactions [16] are the
main features for consideration to understand their dif-
ferences in specificity.
The chemical structures of the selected inhibitors E-64,
E-64-C, leupeptin, ZPACK for the present study are
shown in Fig. 1. The inhibitor, E-64, a trans epoxysuccin-
ic acid attached to a modified dipeptide [(leucylamino)-
4-guanidinobutane] [17,18] is a potent irreversible (cov-
alent type) inhibitor for cysteine proteases in general and
its binding modes with papain [19], actinidin [20], caric-
ain [21] and other lysozomal cysteine proteases [7] have
been reviewed. The other analogue, E-64-C [22], consist-
ing of epoxysuccinyl, leucyl, and an isoamyl group, is also
being studied for its mode of different subsite binding
[23–25]. The efficacy of this kind of inhibitor, makes the
epoxide and its derivatives potential candidates as drug
for the suppression of elevated levels of cysteine protease
activity associated with certain disease states [23].Leu-
peptin is another biologically important peptidyl alde-
hyde (AC-leu-leu-Arginal), a naturally occurring
protease inhibitor [
26] of microbial origin. The arginal residue at the C-ter-
minus of leupeptin is found to be essential for its inhibi-
tory activity which inhibits cysteine proteases as well as
serine proteases [27]. Aldehyde inhibitors such as leu-
peptin are promising lead compounds in the design of
anticancer protease inhibitors [28,29]. They are mostly
composed of amino acids and therefore have few meta-
bolic degradation products that are toxic [27].
ZPACK (N-benzoyloxycarbonyl-L-phenylalanine-L-ala-
nylchloromethyl ketone) [17,18], a substrate – like syn-
thetic inhibitor [30], is specifically designed for cysteine
proteases.
We have done model enzyme-inhibitor complexes for
which no crystal structure is available with a view that,
these structural study of the complexes by modeling
along with the x-ray structures will afford further insight
and complementary information in this area.
Results and discussion
All the inhibitors selected for the present study (E-64, E-
64-C, Leupeptin, ZPACK) can form the covalent bond
with active site Cys 25 Sγ  atom (with distance ~1.80 Å) of
each cysteine proteases. This crucial interactional step
which is mainly manifested in their inhibitory activity
seems to remain conserved in all of our considered thiol
proteases (papain, caricain, chymopapain, actinidin,
calotropin DI) belonging to papain superfamily. The
study reveals that each of the inhibitor molecule forms
hydrogen bonds with the S1 subsite residues of enzyme
molecule almost in a same fashion (Table 1I) as were ob-
served in x-ray structures. The main residues that are in-
volved in the conserved interactions are Cys 25 Sγ , Cys 25
amide nitrogen, the side chain of Gln 19 Nε 2H, His 159
Nδ 1H and in some cases carbonyl oxygen of Asp 158. The
other residue Gly 66 offers its carbonyl oxygen and
amide nitrogen to form hydrogen bond with the back-
bone of inhibitor molecule in most of the cases which are
shown in Table 1I. It is observed that all these interac-
tions help to orient the inhibitor molecule suitably in the
active site cleft for the required nucleophilic attack by the
active Cys 25 Sγ  atom in the complex structure [31]. The
S1-P1interactions of each of the inhibitor with the pro-
teases papain, actinidin, caricain, chymopapain and
calotropin DI are included in Table 1I. Both the MD sim-BMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
Figure 1
Chemical structures of Leupeptin, E-64-C, E-64 and ZPACK
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ulation study and solved enzyme-inhibitor crystal struc-
ture of papain superfamily reveal, although S1-P1
interaction remains conserved / similar in all cases, how-
ever essential differences arise mainly at the S2-P2 and
S3-P3 side chain interaction sites, depending on the ami-
no acid residues constituting the respective sites of the
proteases. The reaction propensities of the enzyme resi-
dues of the model enzyme-inhibitor complexes can be
looked from DASA results (Fig. 6 – Fig. 9) which show
distinctly the residues involved in electrostatic and hy-
drophobic interaction with the E-64, E-64-C, Leupeptin,
ZPACK. The interaction pattern obtained from MD-sim-
ulation study indicates that the differential interaction in
the S2 subsite is a dominant factor in defining the sub-
strate specificity of cysteine proteases of papain family.
This S2 subsite, which is generally hydrophobic in na-
ture, is the best defined substrate binding site that de-
served the term pocket and involves the residues both
from -R and -L domain of enzyme [31]. Table 2II shows
the involved residues of the selected proteases in S2 sub-
site region. Another residue (205, papain numbering)
Ser for papain, Met (211) for actinidin, Gln (205) for calo-
tropin DI at the back of S2 pocket is found to play a sig-
nificant role in deciding the subtrate specificity of these
enzymes at the P2 position of an inhibitor. The residues
involved in S3 binding site (Table 2II) are generally
found to be present on the enzyme surface and the inter-
action seems to prevail only in the side chain region with
no main chain interaction.
Probable interaction of the inhibitors with the active site 
residues ofActinidin, Chymopapain, Caricain and Calotro-
pin DI
Binding mode of E-64 and E-64-C to proteases (Caricain, Chymopa-
pain, Actinidin, Calotropin DI)
All the main chain hydrogen bonding are similar to those
found in papain complexes (Table 1I). The P1 carbonyl
oxygens of E-64 and E-64-C forms hydrogen bonds with
Cys-25 N, Sγ  and Gln 19 Nε 2H. The P2 main chain keto O
and amide NH (Table 3III) make two hydrogen bonds
with NH and O of Gly-66 respectively in most of the cases
forming one residue stretch parallel β  sheet structure. Al-
though the interaction at the S1 subsite of enzymes are
similar in nature for both of the inhibitors, significant
differences arise at the P2 position while making interac-
tion to S2 pocket of the enzymes. P2 residue (Leu) of E-
64 extends inside into the pocket (Fig. 10) whereas cor-
responding P2 residue of E-64-C is located just at the en-
try of the S2 hydrophobic pocket (Fig. 11) interacting
weakly. This point also gets support from DASA study
Figure 2
Stereoscopic view of average over the last 50 ps of MD simulation of the Calotropin DI (backbone only) with E-64 (inhibitor,
ball and stick) complexBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
(Fig. 6 – Fig. 9) for E-64-C-protease complexes where
the peak for one of the leading residue at the S2 pocket is
either very low or absent : Gly-130 (for calotropin DI),
Ile-133 (for chymopapain), Val-133 (for caricain), Ala-
136 (for actinidin). Another significant feature arising
from MD simulation study that also get support from
DASA study, is the residues of proteases especially Asp-
158 in model complexes with E-64, E-64-C show a con-
siderable decrease of their accessibilities suggesting that
the Sn (n = 1–3) subsites of the modeled complexes are
perfectly shielded from the solvent phase by binding with
the inhibitors. The large difference in accessibility may
occur due to many interaction with the inhibitor mole-
cule. There is a second mode of binding for E-64-C to
protease where isoamylamide and leu group of E-64-C
involved in hydrophobic interaction with S2 and S3 site
(contrary to S3 and S2 sites)of proteases respectively, but
it does not change any basic interaction characters at
these sites. In both cases the attack on the active site thiol
group of the cysteine proteases occur from the backside
of the inhibitor resulting in opening of the epoxide ring
and at the same time the formation of a covalent bond
between inhibitor and enzyme [19,20,32,33].
Binding mode of ZPACK and Leupeptin to proteases (Caricain, Chy-
mopapain, Actinidin, Calotropin DI) 
Both ZPACK (N-benzoyloxycarbonyl-L-phenylalanyl
choromethyl ketone) and leupeptin form hydrogen
bonds with the proteases in model complexes in usual
fashion (Table 1I). But the important feature of β  sheet
nature of hydrogen bonding pair formed between the P2
moiety of ZPACK (phe) and Leupeptin (Leu) (Table 3III)
with protease Gly-66 is antiparallel, different from E-64/
E-64-C-protease complexes. The bulky P2 sidechain of
ZPACK, which is Phe, is comfortably accommodated in
the space available making hydrophobic interaction with
all the residues Leu-133, Leu-157 (for chymopapain),
Ala-136, Ile-160, Met-211 (for actinidin), Val-133 and
Val-157 (for caricain), Gly-130, Val-154, Gln-205 (for
calotropin DI). The P2 moiety (Table 3III) extends itself
far inside the S2 pocket and thus away from carbonyl ox-
ygen atom of Asp 158 (Fig. 12) which makes P2 backbone
unable to form hydrogen bond with this residue. DASA
Figure 3
Stereoscopic view of average over the last 50 ps of MD simulation of the Actinidin (backbone only) with E-64-C (inhibitor, ball
and stick) complexBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
study done on the model complexes with ZPACK shows
the peak for Asp-158 for respective enzymes notably less
prominent compared to other complexes. Thus it can be
argued that the absence of this particular H-bond makes
this protease-inhibitor complex less stable compared to
other protease-inhibitor complexes. The residues in-
volved in S2 subsite interaction for ZPACK-protease
model are also same and responsible for preference of
substrate splitting in leupeptin-protease complexes (Fig.
13). P2 moiety of leupeptin and E-64, despite being in-
side the S2 pocket, orients its backbone in such a way that
they are able to form the additional H-bond (Table 1I)
with carbonyl oxygen atom of Asp-158 giving extra sta-
bility to the respective complexes. There is another pock-
et on the left of the cleft called S3 subsite defined by the
segment 61, 67 (papain numbering). The CBZ (benzoy-
loxycarbonyl) group of ZPACK simulating its P3 residue
in the present complex makes aromatic-aromatic inter-
action with phenyl ring of S3 subsite with the shortest
distance from aromatic to aromatic group > 4Å (Fig. 12),
whereas the P3 moiety (Leu) of Leupeptin extends its
sidechain towards the surface of S3 site interacting with
its constituent residues (Fig. 13) of proteases.
Role of water in inhibitor binding to the respective pro-
teases
Water molecules have endowed several important role in
the recognition and stabilization of the interaction be-
tween the ligand and its site. Table IV(4A,5B,6C) gives a
generalized view of interaction with the water molecules
in active site cleft of the proteases. Extensive MD simula-
tion / water dynamics study done on a series of enzyme-
inhibitor complexes from papain plant family demon-
strates some unique features of interesting nature. Con-
formational and dynamic properties of the model
complexes are compared among themselves and with re-
spect to x-ray structure. Solvent networks found in the x-
ray structure were reproduced by the simulation which
was unbiased with respect to the crystalline hydration
structure. These networks seem to play an important role
in the stability of the complexes, evidence of this is found
in the structure of the ligand water interaction of the ac-
tive site. We have identified water molecules, by studying
a series of MD simulated complexes, in the active site
cleft that may be essential in binding of inhibitor in the
cleft.
In all Leupeptin-protease model complexes we found P1
side chain (Arg) of leupeptin is extensively involved in
Figure 4
Stereoscopic view of average over the last 50 ps of MD simulation of the Caricain (backbone only) with Leupeptin (inhibitor,
ball and stick) complexBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
water interaction network (Table IV(4A,5B,6C)). These
water interactions though less in number, are also found
to be present in x-ray structure of papain-leupeptin com-
plex [34]. These interactions support the fact that P1 side
chain of inhibitor, leupeptin, makes few interactions
with S1 site to avoid steric hindrance with carbonyl group
of Gly-23 of protease molecule and extend straight up
out of the cleft towards solvent [8] making a number of
interactions. Moreover the keto oxygen (O3) of ZPACK,
epoxy and carbonyl oxygens of E-64, E-64-C seem to sta-
bilize through strong and weak H-bond with water mol-
ecules within the groove of the enzymes. The amide
nitrogen (N11) of ZPACK and keto oxygen (O9) of E-64,
E-64-C are observed to form H-bonds with water sites
thus assisting the chemical potentiality of P2 site. MD
simulations also characterize some other important ster-
eochemically potential interaction sites of inhibitors in
complexation with different proteases associated with P3
site of E-64, leupeptin, ZPACK and involved in solvation
network within the active site. Guanidinobutane group
of Arg of E-64, keto oxygen (O13, O14) of CBZ of ZPACK
and acetyl keto oxygen of leupeptin involved in water in-
teraction at S3 site with each protease in model complex-
es (Table IV(4A,5B,6C)). The water molecules easily
access the surface region of S3 site of enzyme to interact
with the polar group involved in P3 site of those inhibitor
molecules. Solved x-ray structure of complexes from pa-
pain family also shows this solvation network of P3 site of
inhibitor only for papain-E-64 [19] and actinidin-E-64
[20] complexes but few in number. The inhibitor bonded
water molecular bridging H-bonds of leupeptin acetyl
oxygen directly to protein S2 / S3 subsite residues at
amide oxygen of Val-157 (in caricain) and Gly-66 (in chy-
mopapain) and at side chain Tyr-67-OH group of calo-
tropinDI are more conducive allowing the ligand binding
by Pn...H2O...Sn type of interaction which are evidenced
and are supported from our studies. Thus the hydration
dynamic study on series of modeled complexes helps us
to understand the role of water involved in stabilizing the
inhibitor molecules in S2 / S3 subsite of proteases, where
polar group involved in P3 site of inhibitor may add extra
stability to enzyme-inhibitor complexes by water medi-
ating interactions of ligand and enzyme residues in-
volved in this segment.
The other key feature and the most important one that
has emerged out from the study is the participation of a
key water molecule (marked by ** in Table
IV(4A,5B,6C)) in the vicinity of oxyanion hole within the
active site of proteases which seemingly play a vital role
Figure 5
Stereoscopic view of average over the last 50 ps of MD simulation of the Chymopapain (backbone only) with ZPACK (inhibi-
tor, ball and stick) complexBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
in inhibitor binding. This particular water molecule
found near the region of oxyanion hole, comprising of
Cys 25 NH and Gln 19 Nε 2H, forms hydrogen bond with
the carbonyl / carboxyl oxygen of P1 moiety of inhibitor
at a distance of ~2.63 Å to 3.47 Å [O18 of E-64 and E-64-
C, O3 of ZPACK and mainchainO of Arg of leupeptin]
(Fig. 10 – Fig. 13). This observation when extended to the
solved x-ray structure of papain family either native or
complexed [15,19–21,33,35,36], we found that this par-
ticular water is also present in several of these cases
(PDB codes are 1PPN, 2ACT, 2AEC, 1MEG, 1GEC, 1YAL,
1PPP, 1PE6). This important observation lead us to sug-
gest that the water molecule present in the solved struc-
ture and model complexes may be involved in stabilizing
the inhibitor molecule during nucleophilic attack of
cysteine protease. And perhaps this water which behaves
Figure 6
DASA study of inhibitor-enzyme complexes
Figure 7
DASA study of inhibitor-enzyme complexesBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
like a conserved water, is involved in acylation / deacyla-
tion step during catalysis by proteases in papain family.
Table IV(4A,5B,6C) highlights that for each inhibitor the
interactions are not random, but rather highly specific,
usually involving specific residues / regions of the ligand.
These water molecules contribute directly to the stability
of the complex by holding themselves in the right posi-
tion through network of hydrogen bonds. These water
networks are probably crucial for the stability of protein-
ligand complexes and may be important for any site di-
rected drug design strategies. Thus our observation dem-
onstrates that incorporation of water molecules into the
system improves interpretation and predictive ability of
Figure 8
DASA study of inhibitor-enzyme complexes
Figure 9
DASA study of inhibitor-enzyme complexesBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
the models and are in good agreements with the x-ray
structural analysis of some complexes and offers valua-
ble insights into new characteristics of the ligands which
may be exploited for design of more potent inhibitors.
Material and Method
The different inhibitors (Fig. 1) were docked to the active
site cleft of the selected proteases from the papain family
using chemical intuition and viable interaction strategy.
The position and orientation of these inhibitors in the ac-
Table I: Significant atomic distances (Å) of different catalytic site residues of cysteine proteases with selected inhibitors at S1 - P1 site
E-64 & Protease Papain Caricain Chymo Actinidin Calotropin
[19] [21] papain [20] DI
O5.....66(Gly):N 2.88 2.78 - 2.92 3.37
N10.....66(Gly):O 3.04 2.94 3.23 2.91 3.49
N6.....158(Asp):O 3.27 3.58 3.15 3.60
O18.....159(His):ND1 2.90 2.88 2.76 2.80 3.10
O17.....19(Gln):NE2 2.87 2.74 2.88 2.91 3.22
O17.....25(Cys):N 2.95 3.01 3.05 2.94 3.54
O17.....25(Cys):SG 3.36 3.33 3.24 2.81
E-64-C & Protease Papain Caricain Chymo Actinidin Calotropin
[33] Papain DI
O5...66(Gly):N 3.16 2.88 3.28 3.05 3.21
N10...66(Gly):O 3.46 - 3.30 3.64 -
O17...19(Gln):NE2 2.90 3.35 3.12 3.25 3.18
O17...25(Cys):N 2.75 3.20 3.11 2.36 2.84
O17...25(Cys):SG 2.61 3.35 3.01 3.08 2.79
O18...159(His):ND1 3.76 3.38 3.32 3.56 3.39
N6...158(Asp):O 2.99 3.17 3.27 3.43 3.40
Leupeptin & Protease Papain Caricain Chymo Actinidin Calotropin
[34] Papain DI
2 Leu:N...66(Gly):O 3.05 3.14 3.50 3.24 3.29
2 Leu:O...66(Gly):N 2.78 3.17 3.13 3.09 3.07
3 Arg:N...25(Cys):SG 3.01 3.06 3.26 3.22 3.02
3 Arg:N...158(Asp):O 3.03 2.69 3.09 2.80 2.93
3 Arg:O...19(Gln):NE2 2.88 3.17 3.21 3.17 3.18
3 Arg:O...25(Cys):SG 2.62 2.65 2.66 2.71 2.56
3 Arg:O...25(Cys):N 3.00 3.28 3.50 3.16 3.46
ZPACK & Protease Papain Caricain Chymo Actinidin Calotropin
[30] papain DI
N11...66(Gly):O 2.84 2.98 - 2.85 3.61
O8...66(Gly):N 2.96 3.10 3.29 3.10 2.85
O3...25(Cys):N 3.61 3.25 3.40 2.85 3.84
O3...25(Cys):SG 3.30 3.45 3.18 3.05 3.28
O3...19(Gln):NE2 3.56 3.36 3.60 3.36 3.20
Footnote: The numbers in square brackets are reference numbers In the table, the distances are typed as normal for the modeled complexes and 
x-ray crystallographic values are in italics. Residue numbers are according to papain sequenceBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
tive site cleft was primarily based on the knowledge of x-
ray structures [19–21,30–34,37–39] of different cysteine
proteases with the inhibitors.
Each of the modeled structures was subjected to con-
strained energy minimization to relieve residual strain
maintaining the integrity of the model. The modeling
and energy minimization was done with the InsightII
software package (Molecular Simulations Inc., San Di-
ego, CA, version 95.0) on a Silicon Graphics Indigo work-
station. The minimization was done with the Discover
Platform of the InsightII program with a consistent va-
lence force field (CVFF). The algorithms utilized for min-
imization were typically the conjugate gradient options
in vacuum and were chosen to be distance dependent.
The covalently linked ligand was minimized while the
enzyme backbone was kept rigid using the Discover op-
tion constraint. During energy minimization, in addition
to the usual energy terms (bond, angle, dihedral, im-
proper dihedral, electrostatic and van der Waals), dis-
tance constraints were also introduced initially.
Different selected inhibitors were docked into the caric-
ain [21,40], chymopapain [36], actinidin [35], calotro-
pinDI [41] environments lead by the information of x-ray
crystallographically solved complex structures of pro-
teases from the papain family. The nonbonded interac-
Table II: Residues involved in S2 and S3 sites of different protease systems
Name of the Protease Residues involved in the S2 sites Residues involed in the S3 sites
Papain [14,15] Val-133, Val-157, Ala-160, Tyr-61, Tyr-67
Ser-205, Asp-158, Pro-68
Actinidin [35] Ala-136, Ile-160, Met-211, Asn-61, Tyr-69
Ala-163, Asp-161, Ile70
Caricain [40] Val-133, Val-157, Ser-209, His-61, Tyr-67
Ala-160, Asp-158, Pro-68
Chymopapain [36] Leu-133, Leu-157, Ala-160, Tyr-61, Tyr-67
Asp-158, Gln-68
CalotropinDI [41] Gly-130,Gln-134,Val-154, Tyr-61, Tyr-67
Ala-160,Gln-205,Asp-158,
Tyr-68
Figure 10
Stereoscopic view of probable binding mode of E-64 with the active site residues of Calotropin DIBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
tions included van der Waal's and electrostatic forms
which used the Lenard-Jones and Coulomb functions re-
spectively. The cut off radius for nonbonded interactions
was 30 Å.
Molecular dynamics (MD) simulations of the modeled en-
zyme-inhibitor complex structure
Each of the energy minimized structure was solvated by
a 10 Å layer of water molecules using SOAK option of in-
sight II (Molecular Simulations Inc., San Diego, CA, ver-
sion 95.0). During molecular dynamic simulations and
minimization, a distance dependent dielectric constant
of 1.0 was used. The parameter used was the consistent
valence forcefield (CVFF). Prior to simulations, the co-
ordinates of all the enzyme-inhibitor atoms were fixed
and solvent molecules were minimized using steepest
decent method in all constrained minimizations for 1000
iterations. Finally, the conjugate gradient minimizations
were performed with all atoms free to move until maxi-
mum derivative was < 0.5 Kcal/mol/Å. The minimized
co-ordinates of the whole system were used as a starting
point for NVT (constant volume and temperature) at
300K to generate possible stable conformation. After 20
ps equilibrium stage, the simulations were carried out
using velocity verlet algorithm for another 100 ps. Only
the amino acid residues and solvent within a 12 Å radius
of the inhibitor was permitted to move during simula-
tion; the remainder of protein was fixed throughout the
simulation. Surrounding the sphere of moving residue
and solvent was a layer of waters whose positions were
fixed in order to ensure that none of the moving solvent
molecules escaped from the vicinity of the active site
simulation. The average structures over the last 50 ps of
each kind of MD simulations were taken to find out prob-
able interactions of the inhibitors with the active site res-
idues (Fig 2 – Fig. 5).
Figure 11
Stereoscopic view of probable binding mode of E-64-C with the active site residues of Actinidin
Table III: Residues involved in various subsites of the selected 
inhibitors
Name of the Name of the subsites
inhibitors
P2 P3
E-64 [17,18] Leu Amino-4-guanidinobutane
E-64-C [22,32] Leu Isoamylamide
E-64-C [22,33] Isoamylamide Leu
Leupeptin [26] Leu Leu
ZPACK [30] Phe BenzoyloxycarbonylBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
Figure 12
Stereoscopic view of probable binding mode of ZPACK with the active site residues of Chymopapain
Figure 13
Stereoscopic view of probable binding mode of Leupeptin with the active site residues of CaricainBMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
Table IV (A): Water involved in the interaction inside active site cleft of the enzyme-inhibitor complexes
Papain + Leupeptin[34] Distances in Å Subsites of inhibitor
in interaction
Leup:3Arg:NE 419:OH2 3.28* P1
Leup:3Arg:NH1 437:OH2 2.67* P1
Caricain + Leupeptin
Leup:3Arg:NE 439:OH2 3.21* P1
Leup:3Arg:NE 411:OH2 2.85* P1
Leup:3Arg:NH1 1365:OH2 2.92* P1
Leup:3Arg:NH2 439:OH2 2.85 P1
Leup:3Arg:O 1313:OH2 2.63** P1
Leup:Ac:O 1293:OH2 2.86 P3
Caricain:157:Val:O 1293:OH2 2.78
Chymopapain + Leupeptin
Leup:3Arg:NE 1288:OH2 3.05* P1
Leup:3Arg:NH1 1324:OH2 2.99* P1
Leup:3Arg:NH2 1288:OH2 3.01 P1
Leup:3Arg:NH2 1397:OH2 3.19 P1
Leup:3Arg:O 1505:OH2 2.98** P1
1324:OH2 1402:OH2 2.74
Leup:1Leu:N 1402:OH2 3.32 P2
Leup:Ac:O 1437:OH2 3.13 P3
Chymo:66:Gly:O 1437:OH2 2.74
Actinidin + Leupeptin
Leup:3Arg:NH1 1249:OH2 2.83* P1
Leup:3Arg:NH1 1303:OH2 2.86* P1
Act:158:O 1303:OH2 2.72
Leup:3Arg:NH2 1249:OH2 3.01 P1
Leup:3Arg:NH2 1593:OH2 3.11 P1
Leup:3Arg:O 186:OH2 3.26** P1
Leup:Ac:O 1391:OH2 3.28 P3
Calotropin DI + Leupeptin
Leup:3Arg:NE 1370:OH2 3.23* P1
Leup:3Arg:NH1 1370:OH2 3.17* P1
Leup:3Arg:NH1 1553:OH2 3.49* P1
Leup:3Arg:NH1 1435:OH2 3.37 P1
Leup:3Arg:NH2 437:OH2 2.56 P1
Leup:3Arg:O 1320:OH2 3.33** P1
Leu :Ac :O 1595 :O1 3.00 P3
1595 :OH2 CaloDI:67:Tyr :OH 3.49
Leup:Ac:O CaloDI:67:TYR:OH 3.22 P3
Table IV (B): Water involved in the interaction inside active site cleft of the enzyme-inhibitor complexes
Papain + E-64-C[32,33] Distances in Å Subsites of inhibitor
in interaction
E-64-C (I):O18 232:OH2 2.98** P1
E-64-C(II):O18 389:OH2 2.60** P1
Caricain + E-64-C
E-64-C:O18 1468:OH2 3.47** P1
E-64-C:O17 1520:OH2 3.46 P1
Chymopapain + E-64-C
E-64-C:O18 1464:OH2 2.69** P1
E-64-C:O9 1317:OH2 3.20 P2BMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
Actinidin + E-64-C
E-64-C:O18 1489:OH2 2.85** P1
E-64-C:O9 1152:OH2 3.32 P2
E-64-C:O1 1454:OH2 3.21 P1
CalotropinDI + E-64-C
E-64-C:O18 445:OH2 3.09** P1
E-64-C:O18 441:OH2 3.29** P1
E-64-C:O17 455:OH2 3.21 P1
E-64-C:O9 1299:OH2 2.84 P2
E-64-C:O5 1406:OH2 3.41 P1
1299:OH2 1406:OH2 3.16
Papain + E-64[19]
E-64:O18 217:OH2 2.67** P1
E-64:N17 216:OH2 2.45* P3
Actinidin + E-64[20]
E-64:O18 582H:OH2 2.81** P1
E-64:N17 257H:OH2 3.23* P3
E-64:N15 54H:OH2 3.01
E-64:N17 54:OH2 3.57 P3
E-64:N15 54:OH2 3.01 P3
Caricain + E-64[21]
E-64:O18 310H:O 2.98** P1
Chymopapain + E-64
E-64:O18 302:OH2 3.21** P1
E-64:O9 1357:OH2 2.85 P2
E-64:N18 1128:OH2 3.14 P3
CalotropinDI + E-64
E-64:O18 196:OH2 2.91** P1
E-64:O17 196:OH2 3.39 P1
E-64:O9 1370:OH2 2.94 P2
E-64:N15 1310:OH2 3.43* P3
E-64:N18 1625:OH2 3.25 P3
E-64:N18 1363:OH2 3.06 P3
E-64:N17 1310:OH2 3.22* P3
Table IV (C): Water involved in the interaction inside active site cleft of the enzyme-inhibitor complexes
Papain + ZPACK[30] Distances in Å Subsites of inhibitor in interaction
(No water mediated interaction
was reported)
Caricain + ZPACK
ZPACK:O13 981:OH2 3.01 P3
ZPACK:O3 396:OH2 3.40 P1
ZPACK:O3 402:OH2 2.25** P1
Chymopapain + ZPACK
ZPACK:O13 341:OH2 3.14 P3
ZPACK:O14 377:OH2 3.07 P3
ZPACK:N11 377:OH2 3.42' P2
ZPACK:O3 290:OH2 3.28** P1
Table IV (B): Water involved in the interaction inside active site cleft of the enzyme-inhibitor complexes (Continued)BMC Structural Biology 2001, 1:4 http://www.biomedcentral.com/1472-6807/1/4
All the optimized structures were finally analyzed by
PROCHECK [42].
Solvent accessibility study
The difference accessible surface area (DASA) study of a
protein with and without inhibitor reveals the potential
interactional sites of the protein. In order to estimate the
fit of contact between the protein and the inhibitor, the
difference accessible surface area (DASA) was calculated
using DASA = [ASA (enzyme) – ASA (complex)] where
ASA represents the accessible surface area given by Lee
and Richard [43] (1971). ASA (complex) and ASA (en-
zyme) are the accessible surface area of each residue in a
protease structure with and without the inhibitor respec-
tively. The DASA study, performed on each of the mod-
eled complexes using Biosym (MSI, San Diego, CA,
InsightII package, 95.0 version), shows distinctly the
protease residues involved in electrostatic and hydro-
phobic interaction with the inhibitors. Difference plots of
solvent accessibilities to indicate the interacting residues
of different numbers of papain-family cysteine proteases
are shown in Fig. (6,7,8,9).
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Actinidin + ZPACK
ZPACK:O13 345:O1 2.84 P3
ZPACK:N6 345:OH2 2.47 P1
ZPACK:O3 366:OH2 2.82** P1
Calotropin DI + ZPACK
ZPACK:O13 1279:OH2 3.20 P3
ZPACK:O13 1346:OH2 3.31 P3
ZPACK:O3 1300:OH2 3.09 P1
Foot notes: Names in Italics are x-ray structures Names in normal font are modelled structures * denotes the interactions found both in x-ray and 
modeled structure ** denotes water found near oxyanion hole
Table IV (C): Water involved in the interaction inside active site cleft of the enzyme-inhibitor complexes (Continued)